On February 5, 2024 Papyrus Therapeutics Inc., a biotechnology platform company for the development of potent, multi-cancer, tumor suppressor precision therapies for solid cancers, reported the upcoming poster presentation entitled "Oncolytic Vaccinia Virus Carrying OPCML Tumor Suppressor is active in Epithelial Ovarian Cancer" has been accepted for presentation at the forthcoming AACR (Free AACR Whitepaper) meeting in San Diego in the Immunology category from 9.00am – 12.30pm PT on April 10th (View Source) (Press release, Papyrus Therapeutics, FEB 5, 2024, View Source;utm_medium=rss&utm_campaign=papyrus-therapeutics-to-present-at-aacr-april-5-10-san-diego [SID1234639845]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data demonstrate that vaccinia virus directed OPCML protein expression enhances OVV selectivity against ovarian cancer cells through direct oncolysis, inhibition of specific RTKs, suppression of angiogenesis, and activation of antitumor immune responses synergistically when combined with an anti-PD-1 inhibitor.

According to Papyrus’ co-founder / chief scientific officer, and renowned translational medical oncologist Hani Gabra, PhD FRCP, "A short treatment with novel OVV-OPCML / anti-PD-1 inhibitor combination showed a 50% increase in median survival in the mice studied, an encouraging outcome demonstrating promise as a targeted strategy for ovarian cancer treatment. This is important given the relatively poor treatment results with check-point inhibitors to date in ovarian cancer."